A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy Volunteers

A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy Volunteers

The purposes of this clinical study are

1. To see how the new drug (HMB-003) under study is tolerated in healthy volunteers, and if there are any important side effects.
2. To measure the amount of HMB-003 in the body after injection.

Inclusion Criteria:

• Participant is aged 18 to 50 years, inclusive, at the time of signing informed consent.
• Overall healthy as determined by medical evaluation including physical examination, vital signs, laboratory tests, and ECG.

Exclusion Criteria:

• Participant has a history of clinically significant hypersensitivity to any excipients of the study drug
• Participant is pregnant, breastfeeding, or <6 weeks postpartum.
• Participant has received investigational drug or device in another clinical study within 30 days or 5 half-lives, whichever is longer, before dosing.